Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN057 in hemophilia A or B with inhibitors
NCT06312475Phase 3Active, not recruiting
- Sponsor
- Alphamab Oncology
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Armocibart in hemophilia A, hemophilia B (HB), sponsored by Alphamab Oncology. Started Jan 2024; status: active, not recruiting.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT06312475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312475.